Viewing Study NCT07077551


Ignite Creation Date: 2025-12-24 @ 11:40 PM
Ignite Modification Date: 2026-01-02 @ 1:23 AM
Study NCT ID: NCT07077551
Status: RECRUITING
Last Update Posted: 2025-07-22
First Post: 2025-06-27
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: NALIRIFOX as Second-Line Chemotherapy in Extrapulmonary High-grade Neuroendocrine Neoplasms: a Prospective, Single-center, Single-arm Trial
Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module